Orelabrutinib
- Generic Name
- Orelabrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25N3O3
- CAS Number
- 1655504-04-3
- Unique Ingredient Identifier
- WJA5UO9E10
- Background
Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
- Indication
⑴既往至少接受过一种治疗的成人套细胞淋巴瘤（MCL）患者。
⑵既往至少接受过一种治疗的成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者。
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
- Conditions
- Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 73
- Registration Number
- NCT06504940
- Locations
- 🇨🇳
The First Affiliated Hospital ，Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma
- Interventions
- Radiation: Ultra-low dose radiotherapy
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Target Recruit Count
- 50
- Registration Number
- NCT06503276
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai, China
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
- Conditions
- Mantle Cell Lymphoma (MCL)
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT06496308
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
- Conditions
- CLL/SLL
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Fei Li
- Target Recruit Count
- 60
- Registration Number
- NCT06476899
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
- Conditions
- Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-07-29
- Target Recruit Count
- 36
- Registration Number
- NCT06478472
- Locations
- 🇨🇳
Bing, Xu, Xiamen, Fujian, China
ICP-248 in Combination with Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 226
- Registration Number
- NCT06378138
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital (The First Affiliated Hospital of University of Science and Technology of China), Hefei, Anhui, China
🇨🇳Gansu Provincial People's Hospital, Lanzhou, Gansu, China
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- InnoCare Pharma Inc.
- Target Recruit Count
- 476
- Registration Number
- NCT06363994
- Locations
- 🇨🇳
Fujing Cancer Hospital, Fuzhou, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 62
- Registration Number
- NCT06290817
- Locations
- 🇨🇳
Affiliated hospital of Jiaxing University , the First Hospital of Jiaxing, Jiaxing, China
🇨🇳Ningbo Medical Center LiHuili Hospital, Ningbo, China
🇨🇳Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Zhejiang, China
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
- Conditions
- MALT Lymphoma of StomachHelicobacter Pylori Infection
- Interventions
- Drug: Triple therapy for eradication of Helicobacter Pylori
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT06228963
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Clinical Study of OR for Second-line Treatment of Refractory MZL
- Conditions
- OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Lixia Sheng
- Target Recruit Count
- 39
- Registration Number
- NCT06134284
- Locations
- 🇨🇳
The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
🇨🇳86-574-87085596, Ningbo, Zhejiang, China
🇨🇳The Second Affiliated Hospital of Zhejiang University, Ningbo First Hospital, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.